Biomarker Identification for Breast Cancer
Introduction of Breast Cancer Diagnostic Biomarkers
Biomarkers generally refer to indicators that can be objectively measured and evaluated, reflect physiological or pathological processes, and have biological effects on exposure or therapeutic interventions. Biomarkers are mostly derived from human tissues or body fluids and can cover physiological, biochemical, immune, cellular, and molecular changes. In the field of tumors, biomarkers are usually produced by tumor cells or non-tumor cells, quantifiable biological substances that reflect the existence and changes of tumor cells or non-tumor cells in vivo. Breast cancer (BC) diagnosis has evolved from basic histological diagnosis and classic biomarkers such as tumor grade and size to include not only histological biomarkers but also a comprehensive set of biomarkers based on protein expression, molecular prognosis, and prediction.
Fig. 1. Female breast structure diagram.
BC Biomarkers Development Services
Alfa Cytology can provide you with BC biomarkers development services. Diagnostic tumor biomarkers are an important basis for clinical disease diagnosis. Using diagnostic biomarkers, patients can be classified according to the presence or absence of a specific physiological, pathological, or molecular-level change. The development of effective biomarkers to screen for BC and provide early diagnosis will allow more BC patients to be detected early, treated, and ultimately improve survival. Our services include,
Changes in the expression of specific miRNAs have been shown to represent pathological diseases. Due to their adjustable stability in human blood, they can be used as diagnostic indicators of BC.
Protein biomarkers are measurable molecules that have prognostic value for patients and can be used for BC diagnosis and to indicate the course of BC.
Microbiomes in breast tissue and gut vary by race, stage, and breast tumor subtype. It can be used to study the occurrence, progression, and prognosis of cancer, and it is a very potential biomarker.
CTCs from the liquid biopsy are validated and effective prognostic biomarkers in metastatic BC.
As a viable option capable of simultaneously capturing the spatial and temporal heterogeneity of BC tumors, ctDNA is a biomarker with clinical application value and has broad application prospects in the diagnosis and treatment of BC.
Advantages of Our Services
- Customized service to satisfy customers
- Scientific and rigorous teamwork
- Extensive expertise in BC fundamental research
- Extensive experience in BC biomarkers discovery and development
- Efficient and comprehensive after-sales service
Alfa Cytology is a leading CRO company with extensive experience in BC basic research and biomarkers development, we have advanced technology and a professional team, if you are interested in learning more about our BC diagnostic development services, please do not hesitate to contact us. Our professional and patient staff will get in touch with you as soon as possible.